Table 1.

Subject demographics. Age age at time of presurgical evaluation, Dur duration of epilepsy in years, MRI MRI findings (w.p.f. without pathological findings, AHS Ammon’s horn sclerosis, bilat. bilateral, FCD focal cortical dysplasia), L left, R right, Loc location of seizure onset zone (MT mesial temporal, SMA supplementary motor area, P parietal, F frontal, Fpo frontopolar, Fpa frontoparietal, FT frontotemporal, T temporal), Out epilepsy surgery outcome scale ⁴⁸ (no surgery performed if empty entry), Szr number of clinical seizures; $D_{\mathit{tot}}$ total recording duration in hours, $D_{\mathit{int}}$ total duration of seizure-free periods in hours, $D_{\mathit{pre}}$ total duration of pre-seizure periods in hours; N total number of electrode contacts, $N_{\mathcal{S}}$ number of electrode contacts in functional module “SOZ”; $N_{\mathcal{N}}$ number of electrode contacts in functional module “neighbours”, $N_{\mathcal{O}}$ number of electrode contacts in functional module “others”, $\#{\mathcal{C}}_{\text{pred}}$ number of centralities that identified predictive nodes.

Subj.	Age	Sex	Dur	MRI	Loc	Out	Szr	D${}_{\text{tot}}$	D${}_{\text{int}}$	D${}_{\text{pre}}$	N	$N_{\mathcal{S}}$	$N_{\mathcal{N}}$	$N_{\mathcal{O}}$	$\#{\mathcal{C}}_{\text{pred}}$
1	54	Male	46	R AHS	RMT	2B	1	228	224	4	86	3	2	81	0
2	34	Male	29	L FCD	LF	1A	7	111	85	26	26	5	5	16	4
3	15	Female	10	R AHS	LT,RT		4	162	146	16	66	44	0	22	0
4	45	Female	42	L AHS	LT	1A	1	146	142	4	48	12	2	34	0
5	25	Female	21	w.p.f.	RMT	1A	1	82	78	4	58	10	1	47	0
6	22	Male	23	w.p.f.	RMT	1A	5	94	74	20	74	10	1	63	0
7	57	Male	51	Hamartia	RFPo	1A	3	71	61	10	72	14	11	47	3
8	39	Female	11	R AHS	RT	1A	3	91	79	12	52	11	3	38	0
9	24	Female	23	AHS bilat.	LMT,RMT		2	20	14	6	42	20	0	22	1
10	34	Male	33	L AHS, L FCD	LMT	1A	4	70	54	16	52	20	4	28	0
11	25	Male	24	L AHS	LMT	1A	3	26	17	9	58	3	5	50	0
12	43	Female	27	w.p.f.	LT	1A	3	94	85	9	56	8	0	48	4
13	29	Male	17	L AHS	LMT,RMT		4	92	76	16	120	20	4	96	1
14	38	Male	15	AHS bilat.	LMT	1A	2	52	44	8	46	8	4	34	0
15	44	Female	31	L FCD	LF	1A	1	103	99	4	14	4	0	10	0
16	52	Male	52	L AHS	LMT	1A	1	49	45	4	42	5	4	33	3
17	45	Male	24	w.p.f.	LT,RT		3	116	107	9	72	28	0	44	2
18	31	Female	14	w.p.f.	RT	1A	2	74	69	5	36	11	1	24	3
19	25	Female	6	w.p.f.	LMT,RMT		5	161	142	19	90	8	1	81	4
20	53	Female	13	L AHS	LP	1A	1	46	42	4	24	11	3	10	0
21	62	Female	50	Dysplasia	RFPa		3	94	84	10	56	39	1	16	2
22	44	Female	30	L AHS	LT,RT	1A	3	129	117	12	46	30	0	16	2
23	25	Male	13	R FCD	RFP	1A	3	18	8	10	30	5	4	21	2
24	26	Female	10	Dysplasia	LT	1A	1	26	22	4	16	5	4	7	1
25	54	Female	49	R FCD	RT	1A	1	67	63	4	62	9	7	46	0
26	27	Female	16	w.p.f.	LMT	1A	2	163	155	8	48	10	2	36	4
27	28	Female	25	R AHS	LMT,RMT		2	126	121	5	46	21	1	24	0
28	19	Male	9	AHS bilat.	LFT,RFT		2	47	40	7	78	34	2	42	2
29	26	Female	18	w.p.f.	LMT	2A	3	97	85	12	36	10	0	26	1
30	37	Male	5	R AHS	RMT	1A	2	103	95	8	46	10	4	32	4
31	25	Male	26	L AHS	LFT,RFT		2	32	25	7	78	0	0	78	0
32	37	Male	2	w.p.f.	LMT	1A	4	68	52	16	65	6	0	59	2
33	15	Female	11	L FCD	LFPo	1A	2	36	28	8	30	8	7	15	1
34	24	Male	4	w.p.f.	LMT	1A	2	67	59	8	65	6	3	56	4
35	22	Male	18	Lesion	LFT	1A	3	19	7	12	38	4	2	32	2
36	29	Female	12	w.p.f.	LMT,RMT		2	37	29	8	88	6	1	81	3
37	41	Female	13	w.p.f.	LMT,RM		2	127	119	8	118	13	5	100	4
38	27	Female	13	L FCD	LSMA	1A	2	67	59	8	30	6	7	17	0